Therapeutic efficacy of cyclophosphamide as a function of inhibition of its metabolism
Sladek, N.E.
Cancer Research 32(9): 1848-1854
1972
ISSN/ISBN: 0008-5472 PMID: 4641276 Document Number: 55474
Document emailed within 1 workday
Related Documents
Limpens, J.; Scheper, R.J. 1991: Inhibition of T suppressor cell function by local administration of an active cyclophosphamide derivative at the sensitization site Clinical and Experimental Immunology 84(3): 383-388Fang, J.; Li, W.; Li, D.; Tan, Z. 2014: Baseline proteinuria, urinary osmotic pressure, and renal function as positive predictors of corticosteroids plus cyclophosphamide treatment efficacy in IgA nephropathy Chinese Medical Journal 127(9): 1710-1714
Turner, C.R.; Quinlan, M.F.; Schwartz, L.W.; Wheeldon, E.B. 1990: Therapeutic intervention in a rat model of ARDS: I. Dual inhibition of arachidonic acid metabolism Circulatory Shock 32(3): 231-242
Futami, H.; Jansen, R.; MacPhee, M.J.; Keller, J.; McCormick, K.; Longo, D.L.; Oppenheim, J.J.; Ruscetti, F.W.; Wiltrout, R.H. 1990: Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy Journal of Immunology 145(12): 4121-4130
Richardson, D.R.; Ponka, P. 1994: The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis Journal of Laboratory and Clinical Medicine 124(5): 660-671
Richardson, D.R.; Ponka, P. 1994: The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis Journal of Laboratory and Clinical Medicine 124(5): 660-671
Fiedel, B.A.; Simpson, R.M.; Gewurz, H. 1977: Effects of C-reactive protein on platelet function. III. the role of cAMP, contractile elements, and prostaglandin metabolism in CRP-induced inhibition of platelet aggregation and secretion Journal of Immunology 119(3): 877-882
Fuller, R.W.; Snoddy, H.D. 1991: Role of norfluoxetine in the inhibition of desipramine metabolism and in the inhibition of serotonin uptake after fluoxetine administration to rats Research Communications in Chemical Pathology and Pharmacology 73(1): 31-40
Reidy, G.F.; Mehta, I.; Murray, M. 1989: Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics Molecular Pharmacology 35(5): 736-743
Kaledin, V.I.; Il'nitskaia, S.I. 2011: Metabolism inhibition stimulates, metabolism activation inhibits cancerogenic activity of ortho-aminoazotoluene in mouse liver Voprosy Onkologii 57(2): 216-220
Martínez Hernáez, A. 1992: Symbolic efficacy, biological efficacy. Towards a new analytical and therapeutic model in health care Revista de Enfermeria 15(172): 61-67
Tangjitgamol, S.; Mamusirinitaya, S.; Leelahakorn, S.; Thawaramara, T.; Pataradool, K.; Suekwatana, P.; Sittidilokratna, K. 2005: Efficacy of platinum plus cyclophosphamide in patients with epithelial ovarian cancer Journal of the Medical Association of Thailand 88(9): 1172-1181
Jaruratanasirikul, S.; Cooper, A.D.; Blaschke, T.F. 1992: Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin Drug Metabolism and Disposition: the Biological Fate of Chemicals 20(3): 379-382
Cohen, S.M.; Zenser, T.V.; Murasaki, G.; Fukushima, S.; Mattammal, M.B.; Rapp, N.S.; Davis, B.B. 1981: Aspirin inhibition of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase Cancer Research 41(9 Part 1): 3355-3359
Tangnararatchakit, K.; Tapaneya-Olarn, C.; Tapaneya-Olarn, W. 1999: The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children Journal of the Medical Association of Thailand 82(Suppl 1): S104-S110
Hamada, Y.; Fukagawa, M. 2008: Relationship between lipid and glucose metabolism and bone mineral metabolism : pleiotropic effects of therapeutic agents for diabetes and hyperlipidemia Clinical Calcium 18(5): 671-676
Wańkowicz, Z.; Tymowicz, J.; Korsak, J. 1998: Therapeutic plasma exchanges with cyclophosphamide in the treatment of rapidly progressing glomerulonephritis Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 5(29): 304-306
Duman, V.L. 2002: Therapeutic effect of cyclophosphamide in patients with chronic glomerulonephritis with nephrotic syndrome Terapevticheskii Arkhiv 74(6): 39-41
Uchida, N.; Takeda, Y.; Kasai, H.; Maekawa, R.; Sugita, K.; Yoshioka, T. 1998: Antitumor efficacy of nedaplatin, a novel platinum complex, with cyclophosphamide in murine and human tumor model Anticancer Research 18(5a): 3375-3379
Ylöstalo; Kauppila, A.; Jouppila, P.; Kiviniitty, K.; Vehaskari, A. 1973: Hepatic and adrenocortical function during cyclophosphamide stoss therapy Acta Obstetricia et Gynecologica Scandinavica 52(4): 299-302